CELL BIOLOGY Correction for “Scaffold association factor B (SAFB) is required for expression of prenyltransferases and RAS membrane association,” by Mo Zhou, Leena Kuruvilla, Xiarong Shi, Stephen Viviano, Ian M. Ahearn, Caroline R. Amendola, Wenjuan Su, Sana Badri, James Mahaffey, Nicole Fehrenbacher, Jane Skok, Joseph Schlessinger, Benjamin E. Turk, David A. Calderwood, and Mark R. Philips, which was first published November 30, 2020; 10.1073/pnas.2005712117 (Proc. Natl. Acad. Sci. U.S.A. 117, 31914–31922).
The authors note that Fig. 5 appeared incorrectly. Specifically, in the middle panel of Fig. 5A, one of the bands was erroneously cropped out. The corrected figure and its legend appear below. The authors confirm that the correct image was derived from the same experiments as the other images in the figure, and that the error does not affect the interpretation of the data. The online version has been corrected.
Fig. 5.
Loss of SAFB diminishes membrane association and GTP loading of KRAS4B and sensitizes KRAS4B-dependent lung tumor cells to FTI treatment. KRAS4B-dependent (A549, H358) and KRAS4B-independent (H1437, H1975) lung tumor cells were stably transfected with a nontargeting shRNA or one targeting SAFB and plated untreated or treated with FTI (L-744,832). (A) A549 cells were disrupted by nitrogen cavitation, separated into S and P fractions by ultracentrifugation, and analyzed by immunoblots for the indicated proteins, including cytosolic (RhoGDI) and membrane (cation-independent manose-6-phosphate receptor; CIMPR) markers (Left). Bands were quantified by Li-Cor Odyssey and percent of total RAS in the cytosol is plotted to the Right; n = 3, *P < 0.05. (B) GTP loading of RAS in FTI-treated (25 µM L-744,832) A549 cells normalized to that measured in untreated cells with and without silencing SAFB by shRNA. **P < 0.01, n = 5. (C) The viability (normalized to untreated cells) of cells with and without stably silencing SAFB by shRNA was determined by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay after 6 d of treatment with indicated concentrations of FTI (L-744,832), n = 3. ns, not significant.